TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03754985

Intervention type: DEVICE
Intervention: Hyperbaric oxygen therapy
Description: The study included participants 18 years or older, scheduled for 60 HBOT sessions for any indication.~After signing an informed consent form, the participants underwent a pulmonary function baseline evaluation. Participants were treated in a multiplace chamber (HAUX-Life-Support GmbH) for 60 daily sessions, 5 days a week. Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minute air breaks every 20 minutes. Participants repeated their pulmonary function evaluation after the last HBOT session.~After signing an informed consent form, the participants underwent a pulmonary function baseline evaluation. Participants were treated in a multiplace chamber (HAUX-Life-Support GmbH) for 60 daily sessions, 5 days a week. Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minute air breaks every 20 minutes. Participants repeated their pulmonary function evaluation after the last HBOT session.
Study: NCT02107144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trimetazidine
Description: After being randomized to Trimetazidin and cardiac medication vs. only cardiac medication, patient will undergo scheduled PCI of single, new, native coronary artery lesion using balloon predilatation and subsequent stenting.
Study: NCT02038062

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sevoflurane preconditioning
Description: Preconditioning by transient application of sevoflurane
Study: NCT03642561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radiotherapy ablation
Description: We using Cool Tip system or RITA system to perform RFA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transarterial chemoembolization(TACE)
Description: TACE treatment is a first line treatment for BCLC stage B HCC
Study: NCT06075303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Cycles

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Cycles
Study: NCT02832050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play therapy
Description: See previous description of play therapy intervention arm.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: See previous description of comparator arm.
Study: NCT04180605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional support for preoperative planning of LAA closure procedures
Description: The results of the computational simulations provided by FEops HEARTguideTM will be used in the computational simulation arm as an additional preoperative planning tool and their potential added value will be assessed by comparison to the standard of care arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure
Description: Transcatheter device insertion to exclude the LAA from the cardiac circulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left atrial appendage closure
Description: Transcatheter device insertion to exclude the LAA from the cardiac circulation
Study: NCT02469246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF
Description: 200/10 mg FDC tablet (with boosted 3rd ARV agents) or 200/25 mg FDC tablet (with unboosted 3rd ARV agents) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF
Description: 200/10 mg FDC tablet (with boosted 3rd ARV agents) or 200/25 mg FDC tablet (with unboosted 3rd ARV agents) administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABC/3TC
Description: 600/300 mg FDC tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC/3TC Placebo
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F/TAF Placebo
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3rd ARV agent
Description: An allowed 3rd ARV agent of the participant's pre-existing regimen may include one of the following boosted ARV agents: ritonavir boosted lopinavir (LPV/r), atazanavir (ATV) + ritonavir (RTV), ATV + cobicistat (COBI) or ATV/COBI FDC, darunavir (DRV) + RTV, DRV+COBI or DRV/COBI FDC; or, one of the following unboosted ARV agents: efavirenz (EFV), rilpivirine (RPV), raltegravir (RAL), dolutegravir (DTG), maraviroc (MVC), or nevirapine (NVP).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3rd ARV agent
Description: An allowed 3rd ARV agent of the participant's pre-existing regimen may include one of the following boosted ARV agents: ritonavir boosted lopinavir (LPV/r), atazanavir (ATV) + ritonavir (RTV), ATV + cobicistat (COBI) or ATV/COBI FDC, darunavir (DRV) + RTV, DRV+COBI or DRV/COBI FDC; or, one of the following unboosted ARV agents: efavirenz (EFV), rilpivirine (RPV), raltegravir (RAL), dolutegravir (DTG), maraviroc (MVC), or nevirapine (NVP).
Study: NCT02682836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk with Ease
Study: NCT05740150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TauroLock-Hep100 (taurolidine 1.35%, citrate 4%, heparin 100 IU/mL)
Description: The TauroLock-Hep100 is a lock solution that is instilled in the lumen of a central venous access device after a treatment cycle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heparin lock (heparin 100 IU/mL)
Description: The Heparin lock is a lock solution that is instilled in the lumen of a central venous access device after a treatment cycle.
Study: NCT01309737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 10 mg oral BID, Continuous treatment for 52 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 5 mg oral BID, Continuous treatment for 52 Weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/CP-690,550
Description: 0 mg oral BID, Continuous Treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/CP-690,550
Description: 0 mg oral BID, Continuous Treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
Study: NCT03322358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Naps
Description: After a baseline period, participants in this condition will be provided with the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Naps
Description: After a baseline period, participants in this condition will be provided with the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Naps
Description: After a baseline period, participants in this condition will be provided with the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home sleep aids
Description: After a baseline period, participants in this condition will be provided with a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home sleep aids
Description: After a baseline period, participants in this condition will be provided with a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home sleep aids
Description: After a baseline period, participants in this condition will be provided with a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home sleep aids
Description: After a baseline period, participants in this condition will be provided with a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep incentives
Description: After a baseline period, participants in this condition will be provided with a small payment for each additional minute of sleep over their mean nighttime sleep in the baseline period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep incentives
Description: After a baseline period, participants in this condition will be provided with a small payment for each additional minute of sleep over their mean nighttime sleep in the baseline period.
Study: NCT04587570

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infiltration with PRP and Fat
Description: Infiltration with 0.75 ml PRP and 0.75 ml Fat

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Infiltration with NaCl
Description: Infiltration with 1.5 ml NaCl
Study: NCT04171570

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronary angiography and or Percutaneous coronary Intervention
Description: Radial access punture site

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronary angiography and or Percutaneous coronary Intervention
Description: Radial access punture site
Study: NCT04282954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366
Description: JP-1366, QD
Study: NCT02813460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and strawberry flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and strawberry flavor.
Study: NCT04282954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366
Description: JP-1366, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366
Description: JP-1366, QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JP-1366 placebo
Description: JP-1366 placebo, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 placebo
Description: JP-1366 placebo, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 placebo
Description: JP-1366 placebo, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 placebo
Description: JP-1366 placebo, QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: Esomeprazole 40mg, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole placebo
Description: Esomeprazole placebo, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole placebo
Description: Esomeprazole placebo, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole placebo
Description: Esomeprazole placebo, QD
Study: NCT01203332

Intervention type: BEHAVIORAL
Intervention: Effectiveness of different strategies in HIV testing and linkage to care
Description: HIV testing Linkage to Care

Intervention type: BEHAVIORAL
Intervention: Effectiveness of different strategies in HIV testing and linkage to care
Description: HIV testing Linkage to Care

Intervention type: BEHAVIORAL
Intervention: Effectiveness of different strategies in HIV testing and linkage to care
Description: HIV testing Linkage to Care
Study: NCT03038009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Pantoprazole (40mg qd) will be concomitant used with DAPT
Study: NCT02813460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and strawberry flavor.
Study: NCT03038009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Pantoprazole (40mg qd) will be concomitant used with DAPT
Study: NCT03681080

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leg crossing
Description: As Counter maneuvre legs will be crossed and cognitive tests will be performed.
Study: NCT00747097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine + cetuximab
Description: gemcitabine 1g/m² 3weeks/4 cetuximab 400 mg/m² the first week, then 250 mg/m², every week Every cycle is 8 weeks treatment
Study: NCT00716690

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multi donor stem cell transplantation
Description: stem cell transplantation from 2 donors
Study: NCT03290781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ontamalimab
Description: Participants will receive 1 milliliter (mL) of ontamalimab sterile aqueous buffered solution at an appropriate oncentration to provide an intended dose of drug (25 or 75 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ontamalimab
Description: Participants will receive 1 milliliter (mL) of ontamalimab sterile aqueous buffered solution at an appropriate oncentration to provide an intended dose of drug (25 or 75 mg).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 1 mL of sterile aqueous buffered solution.
Study: NCT01032083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Treatment with citalopram will be initiated at 20mg/day for the first 4 weeks (or one placebo capsule), followed by the option to increase the dose to 40mg per day (or two placebo capsules) for the remainder of the study period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with citalopram will be initiated at 20mg/day for the first 4 weeks (or one placebo capsule), followed by the option to increase the dose to 40mg per day (or two placebo capsules) for the remainder of the study period.
Study: NCT04138745

Intervention type: OTHER
Intervention: Transverse Thoracic Plane Block
Description: A bilateral plane block in the transverse thoracic space
Study: NCT03232619

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CART
Description: Patients will get one course of CART treatment with the dose of 0.5-5\*10\~6/KgBW.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CART
Description: Patients will get one course of CART treatment with the dose of 0.5-5\*10\~6/KgBW.
Study: NCT02356354

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skin biopsy
Description: 2 biopsies are done on the same patient : 20 cutaneous biopsies from post-burn scar and from healthy skin
Study: NCT01868191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benfotiamine
Description: Treatment with 600 mg/day for the first 3 months followed by 300 mg/day for 9 months
Study: NCT02813460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and strawberry flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and cream vanille flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and cream vanille flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and cream vanille flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and cream vanille flavor.
Study: NCT01868191

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for benfotiamine
Description: Treatment with placebo for benfotiamine 600 mg/day for the first 3 months followed by 300 mg/day for 9 months
Study: NCT00904423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: up to 2400 mg; oral tablet
Study: NCT03247972

Intervention type: DRUG
Intervention: Evolocumab
Description: Sixty subjects will be treated with high dose statins for 8 weeks followed by 8 weeks of high dose statin + evolocumab (420mg/4 wk) therapy.
Study: NCT01160926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: Dose finding trial AZD6244 cohort 1 - 50mg bd AZD6244 cohort 2 - 75mg bd~Capsule form, given for 10 days as single agent then for 35 days in combination with standard chemoradiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib (AZD2171)
Description: 10 days single agent dosing with Cediranib then 35 days in combination with standard chemoradiotherapy AZD2171 cohort 1 - 15mg od AZD2171 cohort 2 - 20mg od AZD2171 cohort 3 - 30mg od~Oral tablets
Study: NCT02926677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue-Centered Treatment (CCT)
Description: Identify stress reactions and develop coping skills to deal with them independently. Helps address ongoing traumatic stressors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Focused CBT (TF-CBT)
Description: Identifies negative cognitive/emotional patterns and helps re-frame them. Uses active support from guardians and focuses on emotional and cognitive conditioning. Focuses on discrete past incidents.
Study: NCT01983891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooking course
Description: 6-week nutrition education and cooking course
Study: NCT04275427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LA-400 laser acupuncture
Description: low level laser
Study: NCT03505437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold water condition
Description: Cold water condition of the SECPT. Participants immerse their hand into ice-cold water (0-3°C). During the SECPT, participants are videotyped and monitored. After the SECPT, participants will receive 45 minutes of in-vivo exposure to spiders

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warm water condition
Description: Warm water condition of the SECPT. Participants immerse their hand into warm water (36-37°C). Participants are neither videotyped nor monitored during the whole procedure. After the SECPT, participants will receive 45 minutes of in-vivo exposure to spiders.
Study: NCT02823457

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: VBMI
Description: 12 week values based motivational interviewing intervention with a licensed psychologist
Study: NCT03632642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzylpenicillin
Description: The study drug will be administered for a minimum of 2 weeks (the minimal currently accepted duration of IV therapy for SAB.) For patients who do not fulfill criteria for 2 weeks of therapy, the duration of treatment will be 4 to 6 weeks and will be made by the treating clinician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flucloxacillin
Description: The study drug will be administered for a minimum of 2 weeks (the minimal currently accepted duration of IV therapy for SAB.) For patients who do not fulfill criteria for 2 weeks of therapy, the duration of treatment will be 4 to 6 weeks and will be made by the treating clinician.
Study: NCT05413330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: Intravitreal injection of 4 mg/0.1 mL preservative-free triamcinolone acetonide at the end of phacoemulsification surgery will be injected at 3.5 mm inferolateral and posterior to the limbus.
Study: NCT00370344

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Operation by experts in laparoscopy. The operation may be performed as laparoscopic or converted to an open operation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Small-incision open cholecystectomy
Description: Operation by experts in small-incision open cholecystectomy.
Study: NCT00976755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Everolimus:~10mg daily
Study: NCT05269576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical practice
Description: Period of 5 days where medical students carry out hospital clinical practices with real patients supervised by professionals who teach them at the same time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical simulation
Description: Clinical simulation classes through 2 sessions of 5 simulated cases each day. All students actively participate in one or two of the simulation cases and observed and discussed all the cases in the debriefings of all of them.
Study: NCT01805648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: Subcutaneously dosing of rhTPO is based on screening weight. Subjects will be given rhTPO 300 IU/Kg once daily up to 14 days in the pre-treatment period . When two consecutive platelet counts is above 50×10\^9/L, the subjects will be begin to receive maintenance treatment of rhTPO 300 IU/Kg. In the period of maintenance treatment, starting dosing interval of rhTPO is every other day followed by the interval adjustments for keeping platelet counts between 30×10\^9/L～100×10\^9/L.
Study: NCT00553995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salsalate
Description: Salsalate 3-4 grams per day as tolerated for nine days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03817918

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung ultrasonography
Description: Patients undergoing thoracic surgery under general anesthesia using one-lung ventilation will have lung ultrasonography at 2 predetermined sites at four different time points
Study: NCT04994925

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control ready meal
Description: Supermarket brand lasagne ready meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test ready meal
Description: The Slimming World lasagne ready meal
Study: NCT03063749

Intervention type: DEVICE
Intervention: Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
Description: Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 2.0 mm - 4.0 mm

Intervention type: DEVICE
Intervention: Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
Description: Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 4.5 mm - 5.0 mm